Guest Contributor


Organizations:
Dacha Capital, Franc-Or Corp, Innovatech Grand Montréal, and URRMA Biopharma

URRMA shareholders invest additional $2 million

Guest Contributor
February 11, 2002

Shareholders in URRMA Biopharma have exercised their options for an additional investment of $2 million in the Montreal-based developer of products to diagnose and treat HIV infection. Franc-Or Corp invested $1 million while Innovatech Grand Montréal and Dacha Capital invested $500,000 each. Franc-Or now holds a 26% interest in URRMA. The new funding is for working capital and R&D leading to commercialization of anti-R7V diagnostic kits...


Other News

Diabetogen completes first round financing

Catena Networks completes US$75-million financing

Bioxel enters intotwo R&D collaborations

SR Telecom acquires US wireless technology






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.